Role of Oxidative Stress in Drug-Induced Kidney Injury

Keiko Hosohata

Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Osaka 569-1094, Japan; hosohata@gly.oups.ac.jp; Tel.: +81-72-690-1271

Academic Editor: Satohiro Masuda
Received: 1 September 2016; Accepted: 18 October 2016; Published: 1 November 2016

Abstract: The kidney plays a primary role in maintaining homeostasis and detoxification of numerous hydrophilic xenobiotics as well as endogenous compounds. Because the kidney is exposed to a larger proportion and higher concentration of drugs and toxins than other organs through the secretion of ionic drugs by tubular organic ion transporters across the luminal membranes of renal tubular epithelial cells, and through the reabsorption of filtered toxins into the lumen of the tubule, these cells are at greater risk for injury. In fact, drug-induced kidney injury is a serious problem in clinical practice and accounts for roughly 20% of cases of acute kidney injury (AKI) among hospitalized patients. Therefore, its early detection is becoming more important. Usually, drug-induced AKI consists of two patterns of renal injury: acute tubular necrosis (ATN) and acute interstitial nephritis (AIN). Whereas AIN develops from medications that incite an allergic reaction, ATN develops from direct toxicity on tubular epithelial cells. Among several cellular mechanisms underlying ATN, oxidative stress plays an important role in progression to ATN by activation of inflammatory response via proinflammatory cytokine release and inflammatory cell accumulation in tissues. This review provides an overview of drugs associated with AKI, the role of oxidative stress in drug-induced AKI, and a biomarker for drug-induced AKI focusing on oxidative stress.

Keywords: acute kidney injury; acute interstitial nephritis; acute tubular necrosis; oxidative stress; early biomarker; vanin-1

1. Introduction

The kidney is an organ that performs a number of essential functions in the body: the clearance of endogenous waste products, the control of volume status, the maintenance of electrolyte and acid-base balance, and endocrine function. Especially, the metabolism and elimination of administered therapeutic and diagnostic agents as well as environmental exposures are major functions. The kidney is exposed to a larger proportion and higher concentration of drugs and toxins than other organs through the secretion of ionic drugs by tubular organic ion transporters across the luminal membranes of the tubule [1], and through the reabsorption of filtered toxins into the lumen of the tubule. Therefore, renal tubular epithelial cells are at greater risk for injury [2,3]. Indeed, drug-induced kidney injury is a serious problem in clinical practice and accounts for 19%–26% of cases with acute kidney injury (AKI) among hospitalized patients [4]. Moreover, AKI causes a severe condition associated with high probabilities of developing progressive chronic kidney disease or end-stage renal disease, thus leading to high mortality rates [5]. Currently, AKI is defined by the Acute Kidney Injury Network (AKIN) as an absolute increase in Scr levels of at least 0.3 mg/dL or a relative Scr increase of more than or equal to 50% within 48 h [6]. However, in some cases, this definition is not applied. For example, tacrolimus-induced AKI in liver transplant recipients is diagnosed by an increase in Scr level of 50% within a continuous 96 h, because the changes in Scr caused by tacrolimus is gradual and difficult to
evaluate according to the AKIN criteria [7]. On the other hand, contrast-induced AKI is diagnosed by an early increase in Scr (within 12 h) [8].

2. Drugs Responsible for AKI

AKI includes acute tubular necrosis (ATN) and acute interstitial nephritis (AIN). Table 1 shows commonly prescribed drugs which are known to cause AKI, which is due to ATN or AIN.

| Type of Damage | Drug          | Pharmacological Class          | References |
|----------------|---------------|-------------------------------|------------|
| ATN            | Cisplatin     | Chemotherapeutic agents       | [9]        |
|                | Ifosfamide    | Chemotherapeutic agents       | [10]       |
|                | Pemetrexed    | Chemotherapeutic agents       | [11,12]    |
|                | Gentamycin    | Antibiotics                   | [13,14]    |
|                | Kanamycin     | Antibiotics                   | [15]       |
|                | Streptomycin  | Antibiotics                   | [15]       |
|                | Tobramycin    | Antibiotics                   | [15]       |
|                | Colistin      | Antibiotics                   | [16,17]    |
|                | Amphotericin B| Antifungal                    | [18]       |
|                | Foscarnet     | Antiviral agents              | [19]       |
|                | Adefovir      | Antiviral agents              | [20]       |
|                | Cidofovir     | Antiviral agents              | [20]       |
|                | Tenofovir     | Antiviral agents              | [20]       |
|                | Iopromide     | Radiocontrast                 | [21]       |
|                | Cyclosporine A| Immunosuppressive             | [22]       |
|                | Tacrolimus    | Immunosuppressive             | [23]       |
|                | Pamidronate   | Bisphosphonate                | [24]       |
|                | Zoledronic acid| Bisphosphonate               | [25]       |
|                | Acetaminophen | Analgesic                     | [26]       |
| AIN            | Penicillins   | Antibiotics                   | [27,28]    |
|                | Cephalosporins| Antibiotics                   | [29,30]    |
|                | Quinolones    | Antibiotics                   | [31–33]    |
|                | Vancomycin    | Antibiotics                   | [34,35]    |
|                | Rifampicin    | Antibiotics                   | [36,37]    |
|                | NSAIDs        | Anti-inflammatory, analgesic, antipyretic | [38] |
|                | Omeprazole    | Proton pump inhibitors        | [39]       |
|                | Ipilimumab    | Immune check point inhibitors | [40]       |
|                | Nivolumab     | Immune check point inhibitors | [40]       |

ATN: acute tubular necrosis; AIN: acute interstitial nephritis; NSAIDs: nonsteroidal anti-inflammatory drugs.

As for ATN, the renal proximal tubule is commonly damaged by several drugs such as cisplatin [9], aminoglycosides (gentamycin, kanamycin, streptomycin, and tobramycin) [41], amphotericin B [18], antiviral agents (adefovir, cidofovir, and tenofovir) [20], radiocontrast [21], and bisphosphonate [25]. Pathologic characteristics are severe tubular injury including luminal ectasia, marked cytoplasmic simplification, cytoplasmic eosinophilia, loss of brush border, and dropout of tubular epithelia.

AIN is another common cause of AKI. In patients with AKI, approximately 15% are proven to be due to AIN by biopsy [42]. AIN represents an abundant immune response to an exogenously administered medication or toxins. Pathologic characteristic is a diffuse infiltration of lymphocytes, monocytes, plasma cells, and eosinophils into the interstitial compartment. Occasional focus of tubulitis is observed. Many studies show that there is no correlation between the type of offending drug and the histologic findings [43,44]. Generally, renal manifestations of AIN occur with an average delay of approximately ten days [45]. Extrarenal manifestations that indicate a systemic reaction, such as skin eruptions, eosinophilia, and fever, also may occur. Among drugs responsible for AIN, antibiotic agents are most common; however, nonsteroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs) are also offenders. Recently, PPIs have become one of the most common causes of
AIN [46]. In a large nested cohort study, the unadjusted odds ratio for AIN was 5.16 for current versus past PPI use [47]. This effect was obvious in the elderly. This is because of an increased susceptibility in the aging kidney, and because of a higher intake of medications in these patients. Of note, when comparing antibiotic-AIN with PPI-AIN in the elderly, those with antibiotic-AIN exhibited more severe AKI at the time of biopsy [47].

3. Mechanism of AKI

In the setting of ATN, the renal proximal tubular epithelium undergoes a complex series of events involving a temporal progression through the loss of polarity and cytoskeletal integrity, necrosis, and apoptosis [48–51]. Subsequently, necrosis induces inflammation. Necrotic cells release danger-associated molecular patterns (DAMPs) and alarmins from several intracellular compartments. DAMPs are molecules with other proinflammatory functions under normal conditions that turn into danger signals only once being released by cell death and by alerting the innate immune system via a group of pattern recognition receptors (PRRs) on the surface or inside other cells. By contrast, alarmins are a heterogeneous group of preformed proinflammatory molecules that are released by cell death from stores inside the cell [52,53]. The release of DAMPs and alarmins induces inflammation, which implies the recruitment of cytokine-producing leukocytes into the peritubular interstitium. Inflammation accelerates tubular injury [54] and involves potential triggers of necroptosis such as TNF-α [55]. In turn, TNF-α and other cytokines drive necroptosis as a secondary cell death category contributing to tubular necrosis and renal dysfunction. This sets up the auto-amplification loop of necroinflammation [56].

Another mechanism underlying ATN is oxidative stress. Proximal tubular toxicity develops due to direct nephrotoxic effects such as mitochondrial dysfunction, lysosomal hydrolase inhibition, phospholipid damage, and increased intracellular calcium concentration, leading to formation of reactive oxygen species (ROS) with injurious oxidative stress. For example, cisplatin, which induces ATN, invokes oxidative stress, and its pathological conditions under which ROS generates are associated with three mechanisms. First, cisplatin is actuated into a highly reactive form, which can rapidly react with thiol-containing molecules including glutathione (GSH), a well-recognized cellular antioxidant [57,58]. The depletion or inactivation of GSH and related antioxidants leads to the accumulation of endogenous ROS within the cells. It activates signaling pathways, mitogen-activated protein kinase (MAPK), P53 and possibly P21, leading to renal tubular cell death. Subsequently, ROS contribute to the fibrotic process either directly or indirectly via enhanced inflammation. Fibrosis and inflammation itself might feedback to the pathway and further increase ROS formation or stimulate the production of cytokines and growth factors. Second, cisplatin may induce mitochondrial dysfunction and increase ROS production via its disrupted respiratory chain [59]. The role of mitochondrial production of ROS in cisplatin-induced renal injury was further indicated by the cytoprotective effects of mitochondria-localized manganese superoxide dismutase [60]. Interestingly, in the same study, expression of catalase in mitochondria did not have significant protective effects, suggesting that superoxide, and not hydrogen peroxide, may be the major injurious oxidant species generated by mitochondria. Finally, cisplatin may induce ROS formation in the microsomes via the cytochrome P450 (CYP) enzymes. In CYP2E1-null mice, cisplatin-induced ROS accumulation was attenuated, as was renal injury [61]. Similarly, aminoglycosides-induced AKI is involved in oxidative stress. Accumulation of high concentrations within lysosomes and release into the cell cytoplasm promotes phospholipid membrane interruption, oxidative stress, and mitochondrial injury, which cause proximal tubular cell apoptosis and necrosis, leading to AKI.

The mechanism underlying AIN is not completely understood. AIN represents an exuberant host immune response to an exogeneously administered medication or toxin. A proposed mechanism is that absorption of various plasma proteins and molecules by tubular cells causes secretion of chemotactic and inflammatory mediators in the interstitium. It has been reported that nuclear factor-kappa B (NF-κB), a protein complex that regulates DNA transcription and upregulates inflammatory mediators,
is overexpressed in the kidneys of proteinuric animals [62–65]. Increased trafficking of protein has been seen to upregulate RANTES (regulated on activation normal T cell expressed and secreted) production which is a chemoattractant molecule stimulated by NF-κB [66]. The inhibition of NF-κB has been shown to reduce cortical tubulointerstitial injury in rat models [67].

4. Oxidative Stress and Vanin-1 as a Potential Biomarker for Drug-Induced ATN

In the development of AKI (especially ATN), ROS and subsequent oxidative stress are largely involved. Generally, ROS are produced as a part of normal cellular function. For example, superoxide anion, the most potent ROS compound, has several cellular sources and is generated as a natural by-product of the electron transport chain in mitochondria. However, under pathological conditions, the uncoupling of oxidative phosphorylation and loss of mitochondrial membrane integrity induce excessive ROS production from the respiratory chain, especially at Complex I and III. Thus, oxidative stress occurs as a result of the increased activity of free radical-producing enzymes, the decreased activity of free radical-removing enzymes, and insufficient levels of antioxidants. In the meantime, mitochondria are also a critical target of the damaging effects of ROS. Oxidative damage leads to mitochondrial dysfunction and a loss of mitochondrial membrane, triggering mitochondrial permeability transition (MPT) and/or the release of proapoptotic proteins like cytochrome c to induce cell death [68].

Considering that a major mechanism of drug-induced AKI (especially ATN) is oxidative stress, it is reasonable to focus on biomarkers that are involved in oxidative stress. Thus, we prepared human primary renal cells [69], and exposed them to organic solvents with nephrotoxicity such as allyl alcohol, chloroform, ethylene glycol, formaldehyde, and phenol, which are known to induce oxidative stress. Next, we extracted total RNA from the cells and analyzed the data at the probe level (CEL files) with GeneSpring GX10 software (Agilent Technologies, Santa Clara, CA, USA) [69], and a novel potential biomarker for AKI (especially ATN), vanin-1 (VNN1), which is associated with oxidative stress, was found [70]. Vanin-1 (70 kDa), an epithelial glycosylphosphatidylinositol (GPI)-anchored to cell membrane with pantetheinase activity [71,72], is a tissue sensor for oxidative stress. We validated the increase in its mRNA expression in human proximal tubular cell line, HK-2 cells exposed to organic solvents [70]. In line with our data, Yoshida et al. [73] showed that renal vanin-1 increased about 2.7-fold after renal ischemia-reperfusion in rats, a renal injury model that causes oxidative stress. This means that vanin-1 reflects the activation of pathway of oxidative stress. Furthermore, Berruyer et al. [74] reported that the transcription of VNN1 is regulated by oxidative stress. A schematic presentation of the postulated vanin-1 pathway is shown in Figure 1.

In the presence of oxidative stress, antioxidant response-like elements within the promoter region of VNN1 act as stress-regulated targets and enhance VNN1 expression. More cysteamine is produced from hydrolysis of pantetheine. Thus, cysteamine is converted to cystamine, which is an inhibitor of γ-glutamylcysteine synthetase (γGCS), the rate-limiting enzyme of glutathione synthesis [75]. In VNN1−/− mice, which lack cysteamine in tissues, it exhibited resistance to oxidative stress induced by whole-body gamma-irradiation and showed a higher γGCS activity and consequently elevated endogenous stores of GSH, the most potent cellular antioxidant in tissue. This elevated GSH level is correlated with lower ROS concentrations and oxidative damage in tissue and is linked to the survival of animals exposed to stress [74]. These findings for oxidative stress responses supports the reports based on experiments on infection or drug-induced intestinal inflammatory models, where VNN1−/− mice display downregulated inflammation [76].

Although VNN1 transcripts are ubiquitously expressed in mouse organs, the highest levels of VNN1 mRNAs are found in the kidney where the tubular epithelial cells selectively express the VNN1 transcripts, but not glomeruli [72]. This expression pattern was confirmed using the anti-vanin-1 antibody, which detected the molecule at the brush border of kidney tubular cells [72]. In line with this report, we found that vanin-1 localized in renal tubules, but not glomeruli in the nephrotoxicant-induced renal tubular injury [70].
In line with this report, we found that vanin-1 localized in renal tubules, but not glomeruli localized in the nephrotoxicant-induced renal tubular injury [70]. These molecules could be involved in cleavage of vanin-1.

![Diagram of vanin-1 pathway in renal tubular epithelial cells](image)

**Figure 1.** Schematic diagram of the postulated vanin-1 pathway in renal tubular epithelial cells in response to oxidative stress. This overview is based on the works of Dupre et al. [75] and Pitari et al. [72]. An inciting drug (e.g., cisplatin) induces generation of free radical species. Although reactive oxidative stress (ROS) has a positive modulatory role, excessive ROS or inadequate capability of antioxidant scavengers leads to oxidative stress. In the presence of oxidative stress, antioxidant response-like elements within the promoter region of VNN1 act as stress-regulated targets and enhance VNN1 expression. More cysteamine is produced from hydrolysis of pantetheine; cysteamine is then converted to cystamine, which is an inhibitor of γ-glutamyllycitelin synthetase (γ-GCS), the rate-limiting enzyme of glutathione (GSH) synthesis. Consequently, GSH stores decrease and subsequently intensifies the oxidative stress, producing more inflammatory cytokines and chemokines. GPX: glutathione peroxidase; GR: glutathione reductase; GSSG: glutathione disulfide.

The physiologic implication of vanin-1 is the recycling of pantothenic acid (vitamin B5, pantothenate). Pantetheinase hydrolyzes one of the amide bonds of pantetheine recycling pantothenic acid (vitamin B5, pantothenate) and releasing cysteamine [75]. Pantothenate is present in food mostly as CoA, which cannot be directly absorbed through enterocytes, whereas pantothenate freely diffuses across the epithelial barrier. Thus, one might speculate that conversion of CoA into pantothenate requires an extracellular, membrane-bound pantetheinase activity capable of recycling pantothenate in the gut. As with the salvage of vitamin B5 in the gut, it is speculated that the presence of a pantetheinase activity at the brush border of tubular epithelial cells might play a role in the salvage of vitamin B5.

The mechanism under which vanin-1 is cleavage is still unknown. Classically, the GPI-anchored proteins are easily released from the cell surface by phosphatidylinositol (PI)-specific phospholipase C (PI-PLC) purified from bacteria [77], which has been used for identification and characterization of the GPI-anchored proteins, although the enzyme is not specific for GPI. GPI-specific PLC was isolated from trypanosomes and characterized in detail [78]. Although other GPI-hydrolyzing PLC activities were described in rat liver [79] and mouse brain [80], the enzymes responsible for these activities have not been characterized in detail. In mammals, the only purified and well-characterized GPI-specific phospholipase is a D-type phospholipase (GPI-PLD). GPI-PLD, a 115-kDa protein, is present in large amounts in mammalian plasma and is capable of cleaving the inositol phosphate linkage of GPI-anchored proteins [81]. Recently, the angiotensin-converting enzyme (ACE) has been reported to be associated with the shedding various GPI-anchored proteins from the cell surface [82]. These molecules could be involved in cleavage of vanin-1.

Until now, various biomarkers for AKI have been identified, such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1). KIM-1 is a type-1 cell membrane glycoprotein...
upregulated in dedifferentiated proximal tubular epithelial cells \cite{83}. Its ectodomain was shed and could be quantitated in the urine following kidney injury in a rodent model of cisplatin-induced AKI \cite{84}. On the other hand, NGAL expression is induced in epithelial cells upon inflammation or malignancy. The expression of NGAL has been shown to be upregulated in the kidney proximal tubular cells and urine in a murine model following ischemic or cisplatin-induced AKI \cite{85}. Importantly, we showed that the urinary concentration of vanin-1 elevated before the conventional markers such as serum creatinine, urinary N-acetyl-β-D-glucosaminidase (NAG), or both increased in rats with a nephrotoxicant \cite{70}, and cisplatin \cite{86} induced renal tubular injury in the time-course analyses. Furthermore, urinary vanin-1 was shown to be more predictive of the decline in eGFR after the dosing of cisplatin compared with KIM-1, NGAL, and NAG in patients with urothelial carcinoma \cite{87}.

The limitation of urinary vanin-1 as a potential biomarker is as follows: many hospitalized patients are likely to be receiving these drugs due to their systemic inflammation of various etiologies; therefore, it is difficult to differentiate between systemic oxidative stress (e.g., due to sepsis) and oxidative stress in the kidney (e.g., due to cisplatin).

5. Conclusions

Urinary vanin-1 could be a useful biomarker for the detection of drug-induced ATN focusing on oxidative stress. On the other hand, vanin-1 remains to be tested for drugs causing AIN. In addition, there are other mechanisms of drug-induced AKI. Further studies are needed to exploit more favorable biomarkers for drug-induced AKI.

Acknowledgments: This work was supported in part by a Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (26460631 to Keiko Hosohata) and by the Japan Research Foundation for Clinical Pharmacology.

Conflicts of Interest: The author declares no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

AKI acute kidney injury
ATN acute tubular necrosis
AIN acute interstitial nephritis
ROS reactive oxygen species
GSH glutathione

References

1. Inui, K.I.; Masuda, S.; Saito, H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 2000, 58, 944–958. [CrossRef] [PubMed]
2. Tiong, H.Y.; Huang, P.; Xiong, S.; Li, Y.; Vathsala, A.; Zink, D. Drug-induced nephrotoxicity: Clinical impact and preclinical in vitro models. Mol. Pharm. 2014, 11, 1933–1948. [CrossRef] [PubMed]
3. Perazella, M.A.; Moeckel, G.W. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy. Semin. Nephrol. 2010, 30, 570–581. [CrossRef] [PubMed]
4. Mehta, R.L.; Pascual, M.T.; Soroko, S.; Savage, B.R.; Himmelfarb, J.; Ikizler, T.A.; Paganini, E.P.; Chertow, G.M. Spectrum of acute renal failure in the intensive care unit: The picard experience. Kidney Int. 2004, 66, 1613–1621. [CrossRef] [PubMed]
5. Chawla, L.S.; Eggers, P.W.; Star, R.A.; Kimmel, P.L. Acute kidney injury and chronic kidney disease as interconnected syndromes. N. Engl. J. Med. 2014, 371, 58–66. [CrossRef] [PubMed]
6. Mehta, R.L.; Kellum, J.A.; Shah, S.V.; Molitoris, B.A.; Ronco, C.; Warnock, D.G.; Levin, A. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit. Care 2007, 11, R31. [CrossRef] [PubMed]
7. Tsuchimoto, A.; Shinke, H.; Uesugi, M.; Kikuchi, M.; Hashimoto, E.; Sato, T.; Ogura, Y.; Hata, K.; Fujimoto, Y.; Kaido, T.; et al. Urinary neutrophil gelatinase-associated lipocalin: A useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. *PLoS ONE* 2014, 9, e110527. [CrossRef] [PubMed]
8. Pesarini, G.; Lunardi, M.; Ederle, F.; Zivelonghi, C.; Scarsini, R.; Gambharo, A.; Lupo, A.; Vassanelli, C.; Ribichini, F. Long-term (3 years) prognosis of contrast-induced acute kidney injury after coronary angiography. *Am. J. Cardiol.* 2016, 117, 1741–1746. [CrossRef] [PubMed]
9. Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. *Kidney Int.* 2008, 73, 994–1007. [CrossRef] [PubMed]
10. Aleksa, K.; Matsell, D.; Krausz, K.; Gelboin, H.; Ito, S.; Koren, G. Cytochrome p450 3A and 2B6 in the developing kidney: Implications for ifosfamide nephrotoxicity. *Pediatr. Nephrol.* 2005, 20, 872–885. [CrossRef] [PubMed]
11. Michels, J.; Spano, J.P.; Brocheriou, I.; Deray, G.; Khayat, D.; Izzedine, H. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. *Case Rep. Oncol.* 2009, 2, 53–56. [CrossRef] [PubMed]
12. Glezerman, I.G.; Pietanza, M.C.; Miller, V.; Seshan, S.V. Kidney tubular toxicity of maintenance pametrexed therapy. *Am. J. Kidney Dis.* 2011, 58, 817–820. [CrossRef] [PubMed]
13. Kosek, J.C.; Mazze, R.I.; Cousins, M.J. Nephrotoxicity of gentamicin. *Lab. Invest.* 1974, 30, 48–57. [PubMed]
14. Gary, N.E.; Buzzleo, L.; Salaki, J.; Eisengir, R.P. Gentamicin-associated acute renal failure. *Arch. Intern. Med.* 1976, 136, 1101–1104. [CrossRef] [PubMed]
15. Luft, F.C.; Bloch, R.; Sloan, R.S.; Yum, M.N.; Costello, R.; Maxwell, D.R. Comparative nephrotoxicity of aminoglycoside antibiotics in rats. *J. Infect. Dis.* 1978, 138, 541–545. [CrossRef] [PubMed]
16. Wolinsky, E.; Hines, J.D. Neurotoxic and nephrotoxic effects of colistin patients with renal disease. *N. Engl. J. Med.* 1962, 266, 759–762. [CrossRef] [PubMed]
17. Falagas, M.E.; Fragoulis, K.N.; Kasiakou, S.K.; Sermaidis, G.; Michalopoulos, A. Nephrotoxicity of intravenous colistin: A prospective evaluation. *Int. J. Antimicrob. Agents* 2005, 26, 504–507. [CrossRef] [PubMed]
18. Burges, J.L.; Birchall, R. Nephrotoxicity of amphotericin b, with emphasis on changes in tubular function. *Am. J. Med.* 1972, 53, 77–84. [CrossRef] [PubMed]
19. Cacoub, P.; Deray, G.; Baumeilou, A.; Le Hoang, P.; Rozenbaum, M.; Gentilini, M.; Soubrie, C.; Rousselie, R.; Jacobs, C. Acute renal failure induced by foscamet: 4 cases. *Clin. Nephrol.* 1988, 29, 315–318. [PubMed]
20. Izzedine, H.; Launay-Vacher, V.; Deray, G. Antiviral drug-induced nephrotoxicity. *Am. J. Kidney Dis.* 2005, 45, 804–817. [CrossRef] [PubMed]
21. McCullough, P.A. Contrast-induced acute kidney injury. *J. Am. Coll. Cardiol.* 2008, 51, 1419–1428. [CrossRef] [PubMed]
22. Whiting, P.H.; Thomson, A.W.; Blair, J.T.; Simpson, J.G. Experimental cyclosporin a nephrotoxicity. *Br. J. Exp. Pathol.* 1982, 63, 88–94. [PubMed]
23. Wijn, R.M.; Ericzon, B.G.; Tiebosch, A.T.; Buurman, W.A.; Groth, C.G.; Kootstra, G. Toxicology of FK506 in the cynomolgus monkey: A clinical, biochemical, and histopathological study. *Transpl. Int.* 1992, 5 (Suppl. 1), S454–S458. [PubMed]
24. Banerjee, D.; Asif, A.; Striker, L.; Preston, R.A.; Bourgoignie, J.J.; Roth, D. Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity. *Am. J. Kidney Dis.* 2003, 41, E18. [CrossRef]
25. Markowitz, G.S.; Fine, P.L.; Stack, J.L.; Kunis, C.L.; Radhakrishnan, J.; Palecki, W.; Park, J.; Nasr, S.H.; Hob, S.; Siegel, D.S.; et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). *Kidney Int.* 2003, 64, 281–289. [CrossRef] [PubMed]
26. Kleinman, J.G.; Breitenfield, R.V.; Roth, D.A. Acute renal failure associated with acetaminophen ingestion: Report of a case and review of the literature. *Clin. Nephrol.* 1980, 14, 201–205. [PubMed]
27. Baldwin, D.S.; Levine, B.B.; McCluskey, R.T.; Gallo, G.R. Renal failure and interstitial nephritis due to penicillin and methicillin. *N. Engl. J. Med.* 1968, 279, 1245–1252. [CrossRef] [PubMed]
28. Appel, G.B.; Garvey, G.; Silva, F.; Francke, E.; Neu, H.C.; Weissman, J. Acute interstitial nephritis due to amoxicillin therapy. *Nephron* 1981, 27, 313–315. [CrossRef] [PubMed]
29. Drago, J.R.; Rohner, T.J., Jr.; Sanford, E.J.; Engle, J.; Schoolwerth, A. Acute interstitial nephritis. *J. Urol.* 1976, 115, 105–107. [PubMed]
30. Blank, M.L.; Parkin, L.; Paul, C.; Herbison, P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis due to cefoperazone. *Ann. Pharmacother.* 2004, 38, 1446–1448. [CrossRef] [PubMed]

31. Bailey, J.R.; Trotz, S.A.; Philbrick, J.T. Ciprofloxacin-induced acute interstitial nephritis. *Am. J. Nephrol.* 1992, 12, 271–273. [CrossRef] [PubMed]

32. Lo, W.K.; Rolston, K.V.; Rubenstein, E.B.; Bodey, G.P. Ciprofloxacin-induced nephrotoxicity in patients with cancer. *Arch. Intern. Med.* 1993, 153, 1258–1262. [CrossRef] [PubMed]

33. Chatzikyrkou, C.; Hamwi, I.; Clajus, C.; Becker, J.; Hafer, C.; Kielstein, J.T. Biopsy proven acute interstitial nephritis with treatment of moxifloxacin. *BMC Nephrol.* 2010, 11, 19. [CrossRef] [PubMed]

34. Codding, C.E.; Ramseyer, L.; Allon, M.; Pitha, J.; Rodriguez, M. Tubulointerstitial nephritis due to vancomycin. *Am. J. Kidney Dis.* 1989, 14, 512–515. [CrossRef] [PubMed]

35. Wai, A.O.; Lo, A.M.; Abdo, A.; Marra, F. Vancomycin-induced acute interstitial nephritis. *Ann. Pharmacother.* 1998, 32, 1160–1164. [CrossRef] [PubMed]

36. De Vriese, A.S.; Robbrecht, D.L.; Vanholder, R.C.; Vogelaers, D.P.; Lameire, N.H. Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features. *Am. J. Kidney Dis.* 1998, 31, 108–115. [CrossRef] [PubMed]

37. Covic, A.; Goldsmith, D.J.; Segall, L.; Stoicescu, C.; Lungu, S.; Volvot, C.; Covic, M. Rifampicin-induced acute renal failure: A series of 60 patients. *Nephrol. Dial. Transplant.* 1998, 13, 924–929. [CrossRef] [PubMed]

38. Bender, W.L.; Whelton, A.; Beschorner, W.E.; Darwish, M.O.; Hall-Craggs, M.; Slez, K. Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs. Immunologic characterization of the inflammatory infiltrate. *Am. J. Med.* 1984, 76, 1006–1012. [CrossRef] [PubMed]

39. Harmark, L.; van der Wiel, H.E.; de Groot, M.C.; van Grootheest, A.C. Proton pump inhibitor-induced acute interstitial nephritis. *Br. J. Clin. Pharmacol.* 2007, 64, 819–823. [CrossRef] [PubMed]

40. Cortazar, F.B.; Marrone, K.A.; Troxell, M.L.; Ralto, K.M.; Hoenig, M.P.; Brahmer, J.R.; Le, D.T.; Lipson, E.J.; Gelezerman, I.G.; Wolchok, J.; et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. *Kidney Int.* 2016, 90, 638–647. [CrossRef] [PubMed]

41. Rougier, F.; Ducher, M.; Maurin, M.; Corvaisier, S.; Claude, D.; Jelliffe, R.; Maire, P. Aminoglycoside dosages and nephrotoxicity: Quantitative relationships. *Clin. Pharmacokinet.* 2003, 42, 493–500. [CrossRef] [PubMed]

42. Praga, M.; Gonzalez, E. Acute interstitial nephritis. *Kidney Int.* 2010, 77, 956–961. [CrossRef] [PubMed]

43. Markowitz, G.S.; Perazella, M.A. Drug-induced renal failure: A focus on tubulointerstitial disease. *Clin. Chim. Acta* 2005, 351, 31–47. [CrossRef] [PubMed]

44. Gonzalez, E.; Gutierrez, E.; Galeano, C.; Chevia, C.; de Sequera, P.; Bernis, C.; Parra, E.G.; Delgado, R.; Sanz, M.; Ortiz, M.; et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. *Kidney Int.* 2008, 73, 940–946. [CrossRef] [PubMed]

45. Rossert, J. Drug-induced acute interstitial nephritis. *Kidney Int.* 2001, 60, 804–817. [CrossRef] [PubMed]

46. Blank, M.L.; Parkin, L.; Paul, C.; Herbison, P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. *Kidney Int.* 2014, 86, 837–844. [CrossRef] [PubMed]

47. Muriithi, A.K.; Leung, N.; Valeri, A.M.; Cornell, L.D.; Sethi, S.; Fidler, M.E.; Nasr, S.H. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. *Kidney Int.* 2015, 87, 458–464. [CrossRef] [PubMed]

48. Ichimura, T.; Maier, J.A.; Maciag, T.; Zhang, G.; Stevens, J.L. FGF-1 in normal and regenerating kidney: Expression in mononuclear, interstitial, and regenerating epithelial cells. *Am. J. Physiol.* 1995, 269, F653–F662. [CrossRef] [PubMed]

49. Thadhani, R.; Pascual, M.; Bonventre, J.V. Acute renal failure. *N. Engl. J. Med.* 1996, 334, 1448–1460. [CrossRef] [PubMed]

50. Wallin, A.; Zhang, G.; Jones, T.W.; Jaken, S.; Stevens, J.L. Mechanism of the nephrogenic repair response. Studies on proliferation and vimentin expression after 35s-1,2-dichlorovinyl-l-cysteine nephrotoxicity in vivo and in cultured proximal tubule epithelial cells. *Lab. Invest.* 1992, 66, 474–484. [PubMed]
52. Oppenheim, J.J.; Yang, D. Alarmins: Chemotactic activators of immune responses. Curr. Opin. Immunol. 2003, 17, 359–365. [CrossRef] [PubMed]
53. Chan, J.K.; Roth, J.; Oppenheim, J.J.; Tracey, K.J.; Vogl, T.; Feldmann, M.; Horwood, N.; Nanchahal, J. Alarmins: Awaiting a clinical response. J. Clin. Investig. 2012, 122, 2711–2719. [CrossRef] [PubMed]
54. Jang, H.R.; Rabb, H. Immune cells in experimental acute kidney injury. Nat. Rev. Nephrol. 2015, 11, 88–101. [CrossRef] [PubMed]
55. Kurts, C.; Panzer, U.; Anders, H.J.; Rees, A.J. The immune system and kidney disease: Basic concepts and clinical implications. Nat. Rev. Nephrol. 2013, 13, 738–753. [CrossRef] [PubMed]
56. Arany, I.; Safirstein, R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 2003, 23, 460–464. [CrossRef]
57. Siddik, Z.H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22, 7265–7279. [CrossRef] [PubMed]
58. Krüdining, M.; van de Water, B.; de Heer, E.; Mulder, G.J.; Nagelkerke, J.F. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: Mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J. Pharmacl. Exp. Ther. 1997, 280, 638–649. [PubMed]
59. Davis, C.A.; Nick, H.S.; Agarwal, A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: Importance of superoxide. J. Am. Soc. Nephrol. 2001, 12, 2683–2690. [PubMed]
60. Liu, H.; Baliga, R. Cytochrome p450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003, 63, 1687–1696. [CrossRef] [PubMed]
61. Liu, H.; Baliga, R. Cytochrome p450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003, 63, 1687–1696. [CrossRef] [PubMed]
62. Gomez-Chiarri, M.; Ortiz, A.; Lerma, J.L.; Lopez-Armada, M.J.; Mampaso, F.; Gonzalez, E.; Egido, J. Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats. Lab. Investig. 1994, 70, 449–459. [PubMed]
63. Gomez-Chiarri, M.; Ortiz, A.; Gonzalez-Cuadrado, S.; Seron, D.; Emancipator, S.N.; Hamilton, T.A.; Barat, A.; Plaza, J.J.; Gonzalez, E.; Egido, J. Interferon-inducible protein-10 is highly expressed in rats with experimental nephrosis. Am. J. Pathol. 1996, 148, 301–311. [PubMed]
64. Tang, W.W.; Qi, M.; Warren, J.S.; Van, G.Y. Chemokine expression in experimental tubulointerstitial nephritis. J. Immunol. 1997, 159, 870–876. [PubMed]
65. Baeuerle, P.A.; Henkel, T. Function and activation of nf-kappa b in the immune system. Annu. Rev. Immunol. 1994, 12, 141–179. [CrossRef] [PubMed]
66. Zoja, C.; Donadelli, R.; Colleoni, S.; Figliuzzi, M.; Bonazzola, S.; Morigi, M.; Remuzzi, G. Protein overload stimulates rantes production by proximal tubular cells depending on nf-kappa b activation. Kidney Int. 1998, 53, 1608–1615. [CrossRef] [PubMed]
67. Rangan, G.K.; Wang, Y.; Tay, Y.C.; Harris, D.C. Inhibition of nuclear factor-kappab activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int. 1999, 56, 118–134. [CrossRef] [PubMed]
68. Orrenius, S.; Gogvadze, V.; Zhivotovsky, B. Mitochondrial oxidative stress: Implications for cell death. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 143–183. [CrossRef] [PubMed]
69. Oshima, Y.; Kurokawa, S.; Tokue, A.; Mano, H.; Saito, K.; Suzuki, M.; Imai, M.; Fujimura, A. Primary cell preparation of human renal tubular cells for transcriptome analysis. Toxicol. Mech. Methods 2004, 14, 309–316. [CrossRef] [PubMed]
70. Hosohata, K.; Ando, H.; Fujiwara, Y.; Fujimura, A. Vanin-1: A potential biomarker for nephrotoxicant-induced renal injury. Toxicology 2011, 290, 82–88. [CrossRef] [PubMed]
71. Aurrand-Lions, M.; Galland, B.; Bazin, H.; Zakharyev, V.M.; Imhof, B.A.; Naquet, P. Vanin-1, a novel gpi-linked perivascular molecule involved in thymus homing. Immunity 1996, 5, 391–405. [CrossRef]
72. Pitari, G.; Malergue, F.; Martin, F.; Philippe, J.M.; Massucci, M.T.; Chabret, C.; Maras, B.; Dupre, S.; Naquet, P.; Galland, F. Panetheinase activity of membrane-bound Vanin-1: Lack of free cysteamine in tissues of Vanin-1 deficient mice. FEBS Lett. 2000, 483, 149–154. [CrossRef]
73. Yoshida, T.; Kurella, M.; Beato, F.; Min, H.; Ingelfinger, J.R.; Stears, R.L.; Swinford, R.D.; Cullans, S.R.; Tang, S.S. Monitoring changes in gene expression in renal ischemia-reperfusion in the rat. Kidney Int. 2002, 61, 1646–1654. [CrossRef] [PubMed]
74. Berruyer, C.; Martin, F.M.; Castellano, R.; Macone, A.; Malergue, F.; Garrido-Urbani, S.; Millet, V.; Imbert, J.; Dupre, S.; Pitari, G.; et al. Vanin-1+/− mice exhibit a glutathione-mediated tissue resistance to oxidative stress. Mol. Cell. Biol. 2004, 24, 7214–7224. [CrossRef] [PubMed]
75. Dupre, S.; Graziani, M.T.; Rosei, M.A.; Fabi, A.; del Grosso, E. The enzymatic breakdown of pantethine to pantothenic acid and cystamine. *Eur. J. Biochem.* 1970, *16*, 571–578. [CrossRef] [PubMed]

76. Martin, F.; Penet, M.F.; Malergue, F.; Lepidi, H.; Dessein, A.; Galland, F.; de Reggi, M.; Naquet, P.; Gharib, B. Vanin-1−/− mice show decreased nsaid- and schistosoma-induced intestinal inflammation associated with higher glutathione stores. *J. Clin. Investig.* 2004, *113*, 591–597. [CrossRef] [PubMed]

77. Low, M.G. Phosphatidylinositol-specific phospholipase C from staphylococcus aureus. *Methods Enzymol.* 1981, *71 Pt C*, 741–746. [PubMed]

78. Bulow, R.; Overath, P. Purification and characterization of the membrane-form variant surface glycoprotein hydrolase of trypanosoma brucei. *J. Biol. Chem.* 1986, *261*, 11918–11923. [PubMed]

79. Fox, J.A.; Soliz, N.M.; Saltiel, A.R. Purification of a phosphatidylinositol-glycan-specific phospholipase C from liver plasma membranes: A possible target of insulin action. *Proc. Natl. Acad. Sci. USA* 1987, *84*, 2663–2667. [CrossRef] [PubMed]

80. Fouchier, F.; Baltz, T.; Rougon, G. Identification of glycosylphosphatidylinositol-specific phospholipases c in mouse brain membranes. *Biochem. J.* 1990, *269*, 321–327. [CrossRef] [PubMed]

81. Davitz, M.A.; Hereld, D.; Shak, S.; Krakow, J.; Englund, P.T.; Nussenzweig, V. A glycan-phosphatidylinositol-specific phospholipase D in human serum. *Science* 1987, *238*, 81–84. [CrossRef] [PubMed]

82. Kondoh, G.; Tojo, H.; Nakatani, Y.; Komazawa, N.; Murata, C.; Yamagata, K.; Maeda, Y.; Kinoshita, T.; Okabe, M.; Taguchi, R.; et al. Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization. *Nat. Med.* 2005, *11*, 160–166. [CrossRef] [PubMed]

83. Bonventre, J.V. Kidney injury molecule-1 (KIM-1): A urinary biomarker and much more. *Nephrol. Dial. Transplant* 2009, *24*, 3265–3268. [CrossRef] [PubMed]

84. Ichimura, T.; Hung, C.C.; Yang, S.A.; Stevens, J.L.; Bonventre, J.V. Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. *Am. J. Physiol. Ren. Physiol.* 2004, *286*, F552–F563. [CrossRef] [PubMed]

85. Mishra, J.; Mori, K.; Ma, Q.; Kelly, C.; Barasch, J.; Devarajan, P. Neutrophil gelatinase-associated lipocalin: A novel early urinary biomarker for cisplatin nephrotoxicity. *Am. J. Nephrol.* 2004, *24*, 307–315. [CrossRef] [PubMed]

86. Hosohata, K.; Ando, H.; Fujimura, A. Urinary Vanin-1 as a novel biomarker for early detection of drug-induced acute kidney injury. *J. Pharmacol. Exp. Ther.* 2012, *341*, 656–662. [CrossRef] [PubMed]

87. Hosohata, K.; Washino, S.; Kubo, T.; Natsui, S.; Fujisaki, A.; Kurokawa, S.; Ando, H.; Fujimura, A.; Morita, T. Early prediction of cisplatin-induced nephrotoxicity by urinary Vanin-1 in patients with urothelial carcinoma. *Toxicology* 2016, *359–360*, 71–75. [CrossRef] [PubMed]

© 2016 by the author; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).